Industry sponsored symposium

Tuesday, 26 October

07:30 – 08:15 Davos 2

Industry sponsored symposium by AstraZeneca

Cardiorenal Protection in Heart Failure: Role of SGLT2 Inhibition

Chair: Roger Hullin, Lausanne


Roger Hullin, Lausanne

SGLT2 and cardiorenal benefits:
Lessons learned from DAPA-HF and DAPA-CKD

Lars Køber, Copenhagen

Recommendations for SGLT2 inhibitors in prevention and treatment

Giuseppe Rosano, London

Discussion and take-home message

Roger Hullin, Lausanne
12:00 – 13:15 Davos 2

Industry sponsored symposium by Boehringer Ingelheim

Diabetes and Heart Failure: Two Sides of the Same Coin

Chair: Karl Svedberg, Gothenburg

The 2021 ESC HF Guidelines: Recommendations on the use of novel drugs

Marco Metra, Brescia

How to use SGLT2 inhibitors in clinical practice

Roger Lehmann, Zurich

Empagliflozin in heart failure with or without diabetes

Thomas F. Lüscher, London
12:00 – 13:15 Davos 1

Industry sponsored symposium by Bristol Myers Squibb

Recent Advances in Hypertrophic Cardiomyopathy

Chair: Bernard Gersh, Rochester


Bernard Gersh, Rochester

Genetics of hypertrophic cardiomyopathy

Benjamin Meder, Heidelberg

Assessing hypertrophic cardiomyopathy

Saidi Mohiddin, London

Cardiac myosin inhibition: a potential therapeutic principle

Iacoppo Olivotto, Florence

Panel discussion

Key messages

Bernard Gersh, Rochester

End of symposium